Particle.news
Drug Development Drug Efficacy Phase 3 Trials Research Studies Efficacy Studies Patient Outcomes Experimental Treatments Drug Approval Randomized Controlled Trials Phase 2 Trials Phase III Trials Vaccine Development Phase 1 Trials Patient Experiences Pharmaceuticals Treatment Efficacy Vaccine Trials Phase I Trials Cancer Research Obesity Treatments Animal Studies Drug Safety Gene Therapy Trials Drug Trials Cancer Treatment Phase II Trials Animal Models Patient Studies Cancer Therapies Therapeutic Strategies Preclinical Studies Trial Phases Pediatric Trials FDA Approvals Cardiovascular Health FDA Regulations Patient Enrollment Late-Stage Studies Diabetes Medical Research Side Effects Immunotherapy Regulatory Approval Research Funding Pediatric Studies Obesity Treatment Product Development Obesity Randomized Studies Treatment Monitoring Pediatric Research Translational Medicine SURMOUNT-5 Trial FDA Approval Data Analysis Patient Case Studies Patient Care Cardiology Drug Effectiveness Animal Testing Meta-Analysis Oncology Treatment Methods Placebo and Nocebo Effects Puberty Blockers Transgender Healthcare Pivotal Studies HIV Treatment Cost-Effectiveness AREDS Studies Patient Eligibility Surgical Oncology Long-term Studies Epinephrine Products Phase Four Trials Phase 0 Trials Lykos Therapeutics Phase 2/3 Studies Regulatory Affairs Drug Approval Process Cancer Treatments Human Studies Late-Stage Data Evidence-Based Medicine Safety Studies Ethics in Research Outcomes Research National Institutes of Health Diagnostic Tests Pediatric Vaccination Patient-Centered Care Phase Three Trials Data Integrity Weight Management Human Testing Pain Relief Alzheimer's Research NHS Approvals Human Trials Phase 3 Studies
The BiVACOR Total Artificial Heart kept the patient alive for over 100 days before a successful heart transplant, marking a milestone in medical innovation.
